These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 15086599)

  • 1. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
    Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
    J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
    Murphy MD; Rosen HR; Marousek GI; Chou S
    Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
    J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
    Mori N; Imamura M; Kawakami Y; Saneto H; Kawaoka T; Takaki S; Aikata H; Takahashi S; Chayama K;
    J Med Virol; 2009 Apr; 81(4):640-9. PubMed ID: 19235866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
    Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
    Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Arakawa T; Fujimori M; Niinomi T; Ando N; Yasuda S; Sakai K; Kimura J
    J Gastroenterol; 2011 Apr; 46(4):501-9. PubMed ID: 20927636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
    Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.
    Shen C; Hu T; Shen L; Gao L; Xie W; Zhang J
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1898-903. PubMed ID: 17914967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy.
    Veillon P; Payan C; Le Guillou-Guillemette H; Gaudy C; Lunel F
    World J Gastroenterol; 2007 Feb; 13(8):1195-203. PubMed ID: 17451199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy.
    Chen TM; Huang PT; Wen CF; Tung JN; Chow KC; Chen YP
    J Viral Hepat; 2011 Feb; 18(2):119-28. PubMed ID: 20236237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.
    Hayashi K; Katano Y; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Viral Hepat; 2011 Apr; 18(4):280-6. PubMed ID: 20367792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
    Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
    J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis.
    Malta Fde M; Medeiros-Filho JE; Azevedo RS; Gonçalves L; Silva LC; Carrilho FJ; Pinho JR
    Mem Inst Oswaldo Cruz; 2010 Feb; 105(1):92-8. PubMed ID: 20209336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the NS5A gene of hepatitis C virus subtype 1b and response to peg-IFNα-2a/RBV combination therapy in Azerbaijani patients.
    Bokharaei-Salim F; Keyvani H; Salehi-Vaziri M; Sadeghi F; Monavari SH; Mehrnoush L; Alavian SM
    Arch Virol; 2014 Nov; 159(11):2893-9. PubMed ID: 25139545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.